Proteomics

Dataset Information

0

Nuclear proteomics of glioma cells infected with an oncolytic adenovirus


ABSTRACT: Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to enhance tumor tropism and glioma-selective replication. E1A mutant adenovirus Delta-24-RGD has shown favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of cytosolic, nuclear, and secreted glioma proteomes throughout the early time course of Delta-24-RGD infection.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Astrocyte

DISEASE(S): Glioblastoma

SUBMITTER: Enrique Santamaría  

LAB HEAD: Enrique Santamaria

PROVIDER: PXD008023 | Pride | 2018-10-22

REPOSITORIES: Pride

altmetric image

Publications

Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection.

González-Morales Andrea A   Zabaleta Aintzane A   Guruceaga Elizabeth E   Alonso Marta M MM   García-Moure Marc M   Fernández-Irigoyen Joaquín J   Santamaría Enrique E  

Oncotarget 20180724 57


Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to increase the antiglioma efficacy. E1A mutant adenovirus Delta-24-RGD (DNX-2401) has shown a favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understoo  ...[more]

Similar Datasets

2018-12-11 | PXD010256 | Pride
2018-12-11 | PXD011580 | Pride
2018-10-22 | PXD008022 | Pride
2018-10-24 | PXD008036 | Pride
2022-05-11 | GSE197374 | GEO
2018-01-16 | PXD005319 | Pride
2022-03-01 | PXD011713 | Pride
2019-08-06 | PXD014111 | Pride
2019-06-04 | PXD000848 | Pride
2018-12-10 | GSE82083 | GEO